newswire, breaking biotechnology and pharma news

Monday, October 18, 2010 - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected for Second Profile in Influential UK-Based Public Service Review, as Outbreak of Legionnaires Disease Draws Renewed Attention to Dangers of Airborne Bacteria - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected for Second Profile in Influential UK-Based Public Service Review, as Outbreak of Legionnaires Disease Draws Renewed Attention to Dangers of Airborne Bacteria

CENTERVILLE, MA - October 18, 2010 ( newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.

The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.

"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the 'Review' as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."

Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Investor Information:Geaux IR Services, Inc.Toll-Free:

Visit the UVFT showcase profile at Request News and Info on UVFT:
Visit this company:
Disclosure, Disclaimer/ UVFT is a paid advertising client on
Published at - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with - Publish Your News - Send a release -

Disclaimer: The following news is paid for and /or published as information only for our readers. is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:

No comments:

Post a Comment